Altering Chemosensitivity by Modulating Translation Elongation
Open accessThe DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The process of translation occurs at a nexus point downstream of a number of signal pathways and developmental processes. Modeling activation of the PTEN/AKT/mTOR pathway in the Emu-Myc mouse is a valuable tool to study tumor genotype/chemosensitivity relationships in vivo. In this model, blocking translation initiation with silvestrol, an inhibitor of the ribosome recruitment step has been showed to modulate the sensitivity of the tumors to the effect of standard chemotherapy. However, inhibitors of translation elongation have been tested as potential anti-cancer therapeutic agents in vitro, but have not been extensively tested in genetically well-defined mouse tumor models or for potential synergy with standard of care agents. METHODOLOGY/PRINCIPAL FINDINGS: Here, we chose four structurally different chemical inhibitors of translation elongation: homoharringtonine, bruceantin, didemnin B and cycloheximide, and tested their ability to alter the chemoresistance of Emu-myc lymphomas harbouring lesions in Pten, Tsc2, Bcl-2, or eIF4E. We show that in some genetic settings, translation elongation inhibitors are able to synergize with doxorubicin by reinstating an apoptotic program in tumor cells. We attribute this effect to a reduction in levels of pro-oncogenic or pro-survival proteins having short half-lives, like Mcl-1, cyclin D1 or c-Myc. Using lymphomas cells grown ex vivo we reproduced the synergy observed in mice between chemotherapy and elongation inhibition and show that this is reversed by blocking protein degradation with a proteasome inhibitor. CONCLUSION/SIGNIFICANCE: Our results indicate that depleting short-lived pro-survival factors by inhibiting their synthesis could achieve a therapeutic response in tumors harboring PTEN/AKT/mTOR pathway mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This effect likely occurs because harringtonine binds to free 60s subunits, but not those that are joined into an 80s ribosome. Thus, elongating ribosomes are immune to harringtonine, whereas a 60s subunit bound by harringtonine will form an 80s at a start site that does not move forward”
From Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes (2011) · cites this paper as Robert et al., 2009
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Median effect analysis indicated a combination index (CI) below 1 for Dxr+HHT and Rap+Dxr indicative of synergy [40] (Fig 7B).”
BackgroundUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 1×
“40S ribosome (and associated factors) [7].”
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169 · cited 3×
“oncogenes may be too narrow an approach for drug development, but rather targeting nodes that reside downstream of these pathways may offer broader acting therapies [1,2].”
BackgroundThe Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833 · cited 3×
“oncogenes may be too narrow an approach for drug development, but rather targeting nodes that reside downstream of these pathways may offer broader acting therapies [1,2].”
BackgroundRock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524 · cited 1×
“some-inhibitor MG132 [38].”
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 1×
“Several of the proteins that play important regulatory roles in cancer progression and apoptosis have short half-lives (e.g. cyclin D1 (∼25 min)”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446 · cited 1×
“S1), as well as identified as genotype-selective antitumor agents in synthetic lethal screens [41].”
BackgroundTranslational control of gene expression
Sonenberg, N., Hershey, J. W. B., & Mathews, M. B. (2000) · Cold Spring Harbor Laboratory eBooks · Cited by 1,379
Dang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188 · cited 1×
“and c-Myc controls the expression of genes involved in many aspects of cell growth including cell cycle progression and survival”
Background
Research works printed but not linked: 2
- Wendel H-G de Stanchina E Fridman JS Malina A Ray S 2004 Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 332 337 15029198 · DOI · Paper page
- Mills JR Hippo Y Robert F Chen SMH Malina A 2008 mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 105 10853 10858 18664580 PMC2504845 · DOI · Paper page
Cited by
Ingolia, N. T., Lareau, L. F., & Weissman, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.10.002 · Cited by 2,187
“We first stopped new translation using harringtonine, which effectively blocks initiation by inhibiting elongation during the first rounds of peptide bond formation following subunit joining (Fresno et al., 1977; Robert et al., 2009).”
MethodInfluentialIngolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., & Weissman, J. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.086 · Cited by 1,259
Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin
Schneider-Poetsch, T., Ju, J., Eyler, D. E., Dang, Y., Bhat, S., Merrick, W. C., Green, R., Shen, B., & Liu, J. O. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.304 · Cited by 1,014
“304-annotation-312">CHX seemed to slightly stabilize the RNA species, as has been observed befor”
ResultAMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C., Fuerth, B. J., Viollet, B., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.001 · Cited by 911
“Wewould like to thank Connie Krawczyk, Arnim Pause, Jerry Pelletier, Francis Robert, David Shackelford, and Leah Donnelly for technical and administrative help.”
MethodDecoding Human Cytomegalovirus
Stern-Ginossar, N., Weisburd, B., Michalski, A., Le, V. T. K., Hein, M. Y., Huang, S.-X., Ma, M., Shen, B., Qian, S.-B., Hengel, H., et al. (2012) · Science · doi:10.1126/science.1227919 · Cited by 589
For better or for worse: the role of Pim oncogenes in tumorigenesis
Nawijn, M. C., Alendar, A., & Berns, A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2986 · Cited by 481
Prohibitin Ligands in Cell Death and Survival: Mode of Action and Therapeutic Potential
Thuaud, F., Ribeiro, N., Nebigil, C. G., & Désaubry, L. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.02.006 · Cited by 208
Fritsch, C., Herrmann, A., Nothnagel, M., Szafranski, K., Huse, K., Schumann, F., Schreiber, S., Platzer, M., Krawczak, M., Hampe, J., et al. (2012) · Genome Research · doi:10.1101/gr.139568.112 · Cited by 207
“Harringtonine is known to bind free 60S ribosomal subunits and to inhibit elongation of ribosomes after joining of harringtoninebound 60S subunits to an 80S ribosome (Fresno et al. 1977; Robert et al. 2009), leading to well-defined signals in ribosome-profiling experiments.”
BackgroundMartelli, A. M., Evangelisti, C., Chappell, W., Abrams, S. L., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., Libra, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.46 · Cited by 204
McCubrey, J. A., Steelman, L. S., Kempf, C. R., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 171
The biological and therapeutic relevance of mRNA translation in cancer
Blagden, S. P., & Willis, A. E. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.16 · Cited by 177
“Inhibitors of this process might have preferential activity against proteins with short half-lives, such as proto-oncogenes required for cell survival, including c-Myc and cyclin D1”
BackgroundRibosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma
Ruan, Y., Sun, L., Hao, Y., Wang, L., Xu, J., Zhang, W., Xie, J., Guo, L., Zhou, L., Yun, X., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58488 · Cited by 151
Artieri, C. G., & Fraser, H. B. (2014) · Genome Research · doi:10.1101/gr.175893.114 · Cited by 135
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia
Gandhi, V., Plunkett, W., & Cortes, J. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1283 · Cited by 118
“More recently, there has been renewed interest in investigations inmodels of hematologic malignancies (19).”
BackgroundHomoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia
Chen, R., Guo, L., Chen, Y., Jiang, Y., Wierda, W. G., & Plunkett, W. K. (2010) · Blood · doi:10.1182/blood-2010-01-262808 · Cited by 120
Transcription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 95
“Treatment with omacetaxine leads to a rapid decrease in the number of proteins with short half-lives, including the oncogenic cyclin D1 and c-Myc (Robert et al., 2009).”
BackgroundMicoine, K., Persich, P., Llaveria, J., Lam, M., Maderna, A., Loganzo, F., & Fürstner, A. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201300393 · Cited by 92
Targeting the translational machinery as a novel treatment strategy for hematologic malignancies
Hagner, P. R., Schneider, A., & Gartenhaus, R. B. (2010) · Blood · doi:10.1182/blood-2009-09-220020 · Cited by 93
Gelsinger, D. R., Dallon, E., Reddy, R., Mohammad, F., Buskirk, A. R., & DiRuggiero, J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa304 · Cited by 84
“The translation inhibitors harringtonine (HHT) and lactimidomycin have been used in eukaryotic cells to enrich ribosomes at initiation sites by inhibiting elongation during the first rounds of peptide-bond formation after subunit joining (31,44).”
MethodOncogenic AKTivation of translation as a therapeutic target
Hsieh, A. C., Truitt, M., & Ruggero, D. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.241 · Cited by 84
“Recently, it has been shown that targeting ribosome biogenesis through pol I inhibition (CX-5461) or targeting various aspects of translation elongation leads to significant antitumour activity in vivo (Robert et al, 2009; Drygin et al, 2011).”
BackgroundProtein synthesis inhibition and GADD34 control IFN‐β heterogeneous expression in response to dsRNA
Dalet, A., Argüello, R. J., Combes, A. J., Spinelli, L., Jaeger, S., Fallet, M., Manh, T. V., Mendes, A. V., Perego, J., Reverendo, M., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201695000 · Cited by 81
“Harring-tonine effectively blocks translation initiation by inhibiting elongation during the first rounds of peptide bond formation (Robert et al , 2009) and therefore mimics the impact of p-eIF2 a and translation inhibition on IRF3 signaling (Fig 3D).”
Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Wetzler, M., & Segal, D. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049778 · Cited by 81
“Despite this general activity, the short-term effect of omacetaxine on cells is the rapid loss of proteins with short half-lives [7-10].”
BackgroundGenome‐Wide Annotation and Quantitation of Translation by Ribosome Profiling
Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., & Weissman, J. S. (2013) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb0418s103 · Cited by 79
Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A
Cencic, R., Robert, F., Galicia-Vázquez, G., Malina, A., Ravindar, K., Somaiah, R., Pierre, P., Tanaka, J., Deslongchamps, P., & Pelletier, J. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.25 · Cited by 66
Self-citationEmerging Therapeutics Targeting mRNA Translation
Malina, A., Mills, J. R., & Pelletier, J. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012377 · Cited by 65
“This, and perhaps the degradation of other short-lived prosurvival factors, explains some of the synergistic effects observed with different inhibitors of translation elongation in the Burkitt’s-like Em-Myc lymphoma mouse model and would warrant greater study and further evaluation of these drugs in combination therap…”
BackgroundInfluentialSelf-citationSong, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0304 · Cited by 63
“Thiswas also true of the other two oncogenic proteinswithmarkedly short half-lives—cyclinD1 and c-MYC (29).”
BackgroundThe translation inhibitor pateamine A prevents cachexia-induced muscle wasting in mice
Di Marco, S., Cammas, A., Lian, X. J., Kovacs, E. N., Ma, J. F., Hall, D. T., Mazroui, R., Richardson, J., Pelletier, J., & Gallouzi, I. E. (2012) · Nature Communications · doi:10.1038/ncomms1899 · Cited by 67
Self-citationLindqvist, L., Vikstrom, I. B., Chambers, J. M., McArthur, K., Anderson, M. A., Henley, K. J., Happo, L., Cluse, L. A., Johnstone, R. W., Roberts, A. W., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.149 · Cited by 68
“One such inhibitor is homoharringtonine (HHT; Omacetaxine mepesuccinate), which inhibits translation elongation by hindering the peptidyl transferase activity of the ribosome.(10,11) HHT has shown promise in patients with acute myeloid leukemia or chronicmyeloid leukemia (CML) and, importantly, has shown activity in i…”
BackgroundInfluentialPérard‐Viret, J., Quteishat, L., Alsalim, R., Royer, J., & Dumas, F. (2017) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/bs.alkal.2017.07.001 · Cited by 61
Sievert, H., Pällmann, N., Miller, K. K., Hermans-Borgmeyer, I., Venz, S., Sendoel, A., Preukschas, M., Schweizer, M., Böttcher, S., Janiesch, P. C., et al. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.014449 · Cited by 62
Targeting Translation Dependence in Cancer
Malina, A., Cencic, R., & Pelletier, J. (2011) · Oncotarget · doi:10.18632/oncotarget.218 · Cited by 66
“Recent data have suggested that part of HHT’s mechanism of action is its ability to downregulate the short-lived anti-apoptotic and prooncogenic protein Mcl-1 [139, 140], as would be expected from transient exposure to a general protein synthesis inhibitor and perhaps explaining some of the synergistic effects observe…”
BackgroundSelf-citationCortes, J. E., Kantarjian, H. M., Réa, D., Wetzler, M., Lipton, J. H., Akard, L. P., Khoury, H. J., Michallet, M., Guerci‐Bresler, A., Chuah, C. T. H., et al. (2015) · Cancer · doi:10.1002/cncr.29240 · Cited by 53
“Treatment days per cycle, median (range) 9 (1-15) 13 (1-17) 13 (1-15) 13 (10-15) 6 (1-10) 7 (1-14)”
Nemunaitis, J. J., Mita, A. C., Stephenson, J., Mita, M. M., Sarantopoulos, J., Padmanabhan-Iyer, S., Nanda, N., Gleich, L. L., Benichou, A., & Craig, A. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1963-2 · Cited by 53
“In vitro, omacetaxine induces apoptosis in leukemic cells due to a selective decrease in short-lived proteins, including the antiapoptotic proteins Mcl-1 and cMyc [9, 10].”
BackgroundThe Stringency of Start Codon Selection in the Filamentous Fungus Neurospora crassa
Wei, J., Zhang, Y., Ivanov, I. P., & Sachs, M. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.447177 · Cited by 48
“Harringtonine blocks initiation by inhibiting elongation during the first rounds of peptide bond formation after subunit joining, causing ribosomes to accumulate at sites of translation initiation (52, 53).”
BackgroundMethot, S. P., Litzler, L. C., Trajtenberg, F., Zahn, A., Robert, F., Pelletier, J., Buschiazzo, A., Magor, B. G., & Noia, J. M. D. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141157 · Cited by 49
“Note that DidB and CHX have equal effects on translation at the doses used (Robert et al., 2009).”
BackgroundMethodInfluentialSelf-citationc-MYC regulates mRNA translation efficiency and start-site selection in lymphoma
Singh, K., Lin, J., Zhong, Y., Burčul, A., Mohan, P., Jiang, M., Sun, L. L., Yong‐Gonzalez, V., Viale, A. J., Cross, J. R., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181726 · Cited by 45
Therapeutic Opportunities in Eukaryotic Translation
Chu, J., & Pelletier, J. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032995 · Cited by 47
“HHT will block synthesis of all proteins in transformed and normal cells and the selectivity of HHT for CML versus normal cells likely stems from inhibition of synthesis of short-lived oncoproteins to which tumor cells have become addicted, such as MCL-1 and c-MYC (Chen et al. 2006; Robert et al. 2009a).”
BackgroundSelf-citationPopa, A., Lebrigand, K., Barbry, P., & Waldmann, R. (2016) · BMC Genomics · doi:10.1186/s12864-016-2384-0 · Cited by 43
“We compared the pateamine A analog desmethyl,desamino-pateamine A (DMDA-PatA) [17]with the previously used inhibitors harringtonin [18], an elongation inhibitor and puromycin, a structural aminoacyl-tRNA analogue that causes premature chain termination.”
MethodMasi, M., Frolova, L. V., Yu, X., Mathieu, V., Cimmino, A., Carvalho, A., Kiss, R., Rogelj, S., Pertsemlidis, A., Kornienko, A., et al. (2015) · Fitoterapia · doi:10.1016/j.fitote.2015.01.009 · Cited by 38
Oblinger, J. L., Burns, S. S., Akhmametyeva, E. M., Huang, J., Li, P., Ren, Y., Shen, R. Z., Miles‐Markley, B. A., Moberly, A. C., Kinghorn, A. D., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now032 · Cited by 38
“Omacetaxine mepesuccinate (Synribo) is a plantderived alkaloid that binds to the 60S ribosomal subunit, blocking peptide elongation.(37) Synribo is FDA-approved as a third-line treatment for chronic myelogenous leukemia resistant to RTK inhibitors.”
BackgroundWaldman, Y. Y., Geiger, T., & Ruppin, E. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003806 · Cited by 36
“Thus, targeting translation initiation [43,44] and elongation [45] cause a therapeutic response in various tumors.”
BackgroundRibosome Profiling as a Tool to Decipher Viral Complexity
Stern‐Ginossar, N., & Ingolia, N. T. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-054854 · Cited by 35
RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model
Mills, J. R., Malina, A., Lee, T., Paola, D. D., Larsson, O. S., Miething, C., Große, F., Tang, H., Zannis‐Hadjopoulos, M., Lowe, S. W., et al. (2013) · Blood · doi:10.1182/blood-2012-06-434365 · Cited by 36
“To confirm that resistance to ABT-737 could be conferred by endogenous Mcl-1 in ArfEm-myc/Bcl-2 cells, we inhibited Mcl-1 expression with either RNAi or using the translation inhibitor cycloheximide (CHX)— conditions that dramatically reduce MCL-1 protein levels and elicit apoptosis in parental ArfEm-myc lymphomas (su…”
MethodSelf-citationViral Short ORFs and Their Possible Functions
Finkel, Y., Stern‐Ginossar, N., & Schwartz, M. (2017) · PROTEOMICS · doi:10.1002/pmic.201700255 · Cited by 36
“Harringtonine binds to the peptidyltransferase center in disassembled large ribosomal subunits [18,19].”
BackgroundAhmed, W. B., & Etten, R. A. V. (2013) · Hematology · doi:10.1182/asheducation-2013.1.189 · Cited by 31
Wang, L., Zhao, L., Guo, W., Saur, D., Seidler, B., Wang, J., Wang, C., & Qi, T. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26847 · Cited by 34
“The mechanism of action of HHT in CML has been suggested to be the inhibition of protein synthesis and the consequent depletion of Bcr-Abl(30) as well as short-lived proteins such as Mcl-1 and c-Myc.(31) In this study, we investigated whether inhibiting protein synthesis directly with HHT could induce acute apoptosis…”
BackgroundGladstone, M. N., Frederick, B. A., Zheng, D., Edwards, A., Yoon, P., Stickel, S., DeLaney, T., Chan, D. C. F., Raben, D., & Su, T. T. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.008722 · Cited by 31
“These results are in agreement with the finding that Didemnin B, another translation inhibitor that we found in the Drosophila screen, synergizes with doxorubicin in a murine leukemia model (Robert et al., 2009).”
Watari, A., Hasegawa, M., Yagi, K., & Kondoh, M. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.012 · Cited by 31
“Indeed, the neosynthesis of anti-apoptotic myeloid cell leukemia-1 (Mcl-1) and c-myc, which are short-lived proteins that regulate the proliferation and survival of leukemic cells, was inhibited in lymphoma cells in response to HHT treatment [42,43].”
BackgroundTargeting translation regulators improves cancer therapy
Jiang, S., Mo, J.-L., Ji, P., Lei, L., Yin, J., Zhou, H., Liu, Z., & Hong, W. (2020) · Genomics · doi:10.1016/j.ygeno.2020.11.011 · Cited by 30
Garbled messages and corrupted translations
Schneider‐Poetsch, T., Usui, T., Kaida, D., & Yoshida, M. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.326 · Cited by 35
“Recent data suggest that inhibitors of translation elongation seem to be particularly suited for enhancing the efficacy of standard therapeutics, such as doxorubicin, in at least a subset of tumor”
BackgroundOmacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
Li, S., & Chen, Y. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s41786 · Cited by 28
“through shortening their half-lives, including those of MCL-1, cyclin D1, and c-MYC.(52) Although more mechanistic studies”
Wang, H., Yang, H., Holm, M., Tom, H. J., Oltion, K., Al‐Khdhairawi, A. A. Q., Weber, J.-F. F., Blanchard, S. C., Ruggero, D., & Taunton, J. (2022) · Nature Chemistry · doi:10.1038/s41557-022-01039-3 · Cited by 28
Baiz, D., Hassan, S., Choi, Y. A., Flores, A., Karpova, Y., Yancey, D., Pullikuth, A., Sui, G., Sadelain, M., Debinski, W., et al. (2013) · Neoplasia · doi:10.1593/neo.13986 · Cited by 24
“Although general protein synthesis inhibitors have been used in the clinic, they have substantial side effects [54,55].”
BackgroundDCB-3503, a Tylophorine Analog, Inhibits Protein Synthesis through a Novel Mechanism
Wang, Y., Gao, W., Svitkin, Y. V., Chen, A. P.-C., & Cheng, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011607 · Cited by 24
“Translation elongation inhibitors can sensitize chemotherapeutic agents [29,37,38].”
BackgroundCDK11p46 and RPS8 associate with each other and suppress translation in a synergistic manner
Hao, Y., Kong, X., Ruan, Y., Gan, H., Chen, H., Zhang, C., Ren, S., & Gu, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.132 · Cited by 23
Inhibition of translation by cytotrienin A—a member of the ansamycin family
Lindqvist, L., Robert, F., Merrick, W. C., Kakeya, H., Fraser, C. S., Osada, H., & Pelletier, J. (2010) · RNA · doi:10.1261/rna.2307710 · Cited by 21
“In addition, we have previously shown that inhibitors of elongation can sensitize select tumors to the pro-apoptotic properties of the clinical agent doxorubicin (Robert et al. 2009).”
BackgroundInfluentialSelf-citationRagam, S., Kontham, R., Cencic, R., Pelletier, J., & Deslongchamps, P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401799j · Cited by 19
Self-citationGu, Y., Zhou, H., Gan, Y., Zhang, J., Chen, J., Gan, X., Li, H., Zheng, W., Meng, Z., Ma, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3615 · Cited by 19
“However, considering the frequent adverse effects of HHT on the hematological system, gastrointestinal tract and other organs [29, 30, 33], and because HHT also inhibits other signaling molecules such as p-210Bcr-Abl [24], c-myc [22], Mcl-1 [23], we can not rule out the possibility that HHT may have additional targets…”
BackgroundShim, G., Lee, S. B., Choi, J., Lee, S., Kim, C., & Oh, Y. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1317-3 · Cited by 18
“Moreover, several studies demonstrated that over-expression ofMcl-1 contributes drug resistance of cancer cells (29,30) and that the reduction of Mcl-1 expression could sensitize the cancer cell-killing effects of various chemotherapeutics including 5-fluorouracil (31), cisplatin (31), mitoxantrone (29), and DOX (11,3…”
Omacetaxine mepesuccinate for the treatment of leukemia
Kim, T. D., Frick, M., & le Coutre, P. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.613378 · Cited by 20
“The degradation of other shortlived pro-survival factors may also contribute to cytotoxicity and sensitization to other agents [26].”
BackgroundHetherington, A. M., Sawyez, C. G., Sutherland, B. G., Robson, D. L., Arya, R., Kelly, K. B., Jacobs, R. L., & Borradaile, N. M. (2016) · Physiological Reports · doi:10.14814/phy2.12963 · Cited by 18
“The dose and treatment regimen were chosen based on previous work indicating that 50 lg/kg was sufficient to partially inhibit protein synthesis in solid tumors in mice (Robert et al. 2009), and that the half-life of didemnin B in liver is 78 h (Beasley et al. 2005).”
BackgroundMethodInfluentialWilson, R. B., Chen, Y. J., Sutherland, B. G., Sawyez, C. G., Zhang, R., Woolnough, T., Hetherington, A. M., Peters, K. M., Patel, K., Kennelly, J. P., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105208 · Cited by 17
Zhou, H., Xu, R., Gu, Y., Shi, P. F., & Qian, S. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1390229 · Cited by 17
Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells
Okabe, S., Tauchi, T., Tanaka, Y., Katagiri, S., Kitahara, T., & Ohyashiki, K. (2013) · Blood · doi:10.1182/blood-2013-04-494773 · Cited by 16
Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia
Nasr, Z., Dow, L. E., Paquet, M., Chu, J., Kontham, R., Ragam, S., Deslongchamps, P., Porco, J. A. J., Lowe, S. W., & Pelletier, J. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-58 · Cited by 12
“Indeed, in many documented cases, the opposite is observed – that is, enhanced chemotherapy efficacy (synergy) in the presence of compounds that target translation [25,39-41].”
Self-citationContext-dependent translation inhibition as a cancer therapeutic modality
Diamond, P. D., Sauer, P. V., Holm, M., Swanson-Swett, C. J., Ferguson, L., Bratset, N. M., Wienker, G. W., Sim, J. S., Adams, H., Kenner, L. R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69891-2 · Cited by 10
“We, as others 25,26 , hypothesize that translation inhibition would be especially effective for targeting oncogenes with short intrinsic half-life or high turnover 76 , such as MYC, while longer-lived housekeeping genes 77 would not be appreciably impacted, adding an additional layer of…”
Klag, T., Härtel, N., Erben, P., Schwaab, J., Schnetzke, U., Schenk, T., Hochhaus, A., & Rosée, P. G. L. (2012) · Leukemia · doi:10.1038/leu.2011.380 · Cited by 6
Mitchell, S. F., Walker, S. E., Rajagopal, V., Aitken, C. E., & Lorsch, J. R. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0215-2_13 · Cited by 6
Stability and bifurcation analysis of a delayed genetic oscillator model
Gao, C., & Chen, F. (2021) · Nonlinear Dynamics · doi:10.1007/s11071-021-06968-1 · Cited by 5
“For example, experiments revealed the translation elongation inhibitor harringtonine can effectively block initiation by inhibiting elongation during the first rounds of peptide bond formation following subunit joining [9,10], resulting in a delay of about 60 seconds [20].”
BackgroundInhibiting mitochondrial-dependent proteolysis of Mcl-1 promotes resistance to DNA damage
Mills, J. R., Malina, A., & Pelletier, J. (2012) · Cell Cycle · doi:10.4161/cc.11.1.18408 · Cited by 5
Self-citationAnadolu, M. N., & Sossin, W. S. (2020) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190686307.013.20 · Cited by 9
Omacetaxine mepesuccinate for management of chronic myeloid leukemia
Lipton, J. H., & Kim, D. S. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.828589 · Cited by 3
“This prevents synthesis of proteins, including multiple short-lived oncoproteins [52,53], such as c-Myc, which inhibits differentiation [56], cyclin D1, which promotes proliferation [57], and Mcl-1, which retards apoptosis [58].”
BackgroundMultisubunit complex eEF1H in human glial tumors: from mRNA to protein
Veremieva, M. V., Малышева, Т. А., Zozulya, Y., Розуменко, В. Д., Сидорик, Л. Л., KAVSAN, V. M., Negrutskii, B. S., & El'skaya, A. V. (2010) · Biopolymers and Cell · doi:10.7124/bc.000166 · Cited by 3
“It is believed that the elongation factors are essential for the tumor functioning since the inhibition of polypeptide elongation reduced the tumor chemosensitivity [7].”
BackgroundHomoharringtonine is a transdermal granular permeation enhancer
Watari, A., Fujiwara, K., Yagi, K., Tachibana, K., Katsurada, T., Myoui, A., & Kondoh, M. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.067 · Cited by 5
The Helix-Loop-Helix motif of human EIF3A regulates translation of proliferative cellular mRNAs
Volegova, M. P., Hermosillo, C., & Cate, J. H. D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292080 · Cited by 3
Wilson, R. B., Chen, Y. J., Zhang, R., Maini, S., Andrews, T. S., Wang, R., & Borradaile, N. M. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00276.2023 · Cited by 2
Casolari, D. A., & Melo, J. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_7 · Cited by 3
Hwang, J., Singh, N., Braniecki, M., Yavuz, B. G., Tsoukas, M. M., & Quigley, J. G. (2021) · British Journal of Haematology · doi:10.1111/bjh.17715 · Cited by 1
Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance
Yong‐Gonzalez, V., Radu, C., Calder, P. A., Shum, D., Gin, D. Y., Frattini, M. G., & Djaballah, H. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073322175240823104921 · Cited by 3
Bentayeb, H. (2016) · theses.fr (ABES) · doi:10.70675/e9d3a868z56bfz4a6aza457z230cc64e1da9 · Cited by 1
Current and Emerging Therapies Targeting Translation
Galicia-Vázquez, G., & Pelletier, J. (2014) · Springer eBooks · doi:10.1007/978-94-017-9078-9_14
Self-citationAssessment of therapeutic targets in experimental models of Myc-induced lymphoma
Forshell, L. P. (2011)
Genomweite Annotation von Translationsinitiationsstellen in der humanen Monozyten-Zelllinie THP-1
Fritsch, C. (2013) · MACAU: Open Access Repository of Kiel University
Principles of ribosome-associated protein quality control during the synthesis of CFTR
Oldfield, T. J., Torres, R. G., Baier, R. E., Renn, R., & Trentini, D. B. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00883-0
“…the CFTR stalling reporter originates from ribosome collisions, we treated cells with low concentrations of Harringtonine, an inhibitor of translation initiation that interferes with ribosome elongation during the fi rst rounds of peptide bond formation (Ingolia et al, 2011; Robert et al, 2009).”
Daker, M., Ahmad, M., Khoo, A. S. B., Tan, L., Chin, S., Hwang, S. S., & Neilsen, P. M. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2890
“…including transcription factors, proto‑oncoproteins and pro‑survival factors including c‑myc, Cyclin D1 and MCL1, without drastically influencing the translation of ‘strong’ mRNAs (mRNAs with short and unstructured 5'UTRs) that usually encode housekeeping genes like ACTB ( β ‑actin) and GAPDH (12).”
InfluentialSun, J., Drever, L., Ortega, J., & Sossin, W. S. (2025) · Biochemical Society Transactions · doi:10.1042/bst20253066 · Cited by 7
“One study used either homoharringtonine, which blocks the first step of elongation, allowing ribosomes that have already passed this step of elongation to finish translation [50], or pateamine A that blocks initiation during ribosomal scanning [51].”
Structural study of the eukaryotic ribosome
de Loubresse, N. G. (2012) · theses.fr (ABES) · doi:10.70675/a228e931zfe02z4725zad2fz53f91e8c1b78
Role of eIF2α phosphorylation in dendritic cell biology
Mendes, A. V. (2018) · theses.fr (ABES) · doi:10.70675/4925706dz277ez4498z8425z349808388e7d
Chen, Y., Huang, S., Huang, D., Jin, Y., Congcong, S., Su, X., Yang, R., Jiang, J., & Wu, J. (2026) · Cells · doi:10.3390/cells15191788
“As a translation elongation inhibitor, HHT preferentially affects short-lived proteins involved in proliferation and survival, such as c-Myc and Mcl-1 [32].”
Park, J., Yu, Y., Park, H., Bang, H., Lee, J., & Lim, C. (2026) · Molecules and Cells · doi:10.1016/j.mocell.2026.100407
RAPPL-Seq Enables Rapid, High-Sensitivity Ribosome Profiling of Scarce SamplesPreprint
Park, A., Szkop, K. J., Lim, C., Erath, J., Huang, J., Mathios, D., Dai, Z., He, X., Pavlovic‐Djuranovic, S., Larsson, O. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.20.760540
Metadata
- Authors
- Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J.
- Affiliations
- McGill University (CA)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Pelletier, Jerry
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-05-01
- Volume
- 4
- Issue
- 5
- Pages
- e5428
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2671598
- OpenAlex
- W2012346470
- Cited by
- 90
- References
- 67
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 3 · 2015: 6 · 2014: 8 · 2013: 13 · 2012: 12
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Canadian Institutes of Health Research (79385_1)
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- chemosensitivity, chemoresistance, Eμ-Myc lymphoma, homoharringtonine, bruceantin, didemnin B, cycloheximide, doxorubicin synergy, apoptosis, Mcl-1, cyclin D1, c-Myc, eIF4E, TSC2, proteasome inhibition, ribosome recruitment
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Homoharringtonine, Animals, Base Sequence, Cycloheximide, Female, Harringtonines, Lymphoma, Mice, Inbred C57BL, Mutation, Peptide Chain Elongation, Translational, Genes, myc, Proto-Oncogene Proteins c-myc, DNA Primers, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Genes, bcl-2, Cyclin D1, Tumor Suppressor Proteins, Quassins, Eukaryotic Initiation Factor-4E, Cell Line, Tumor, Depsipeptides, PTEN Phosphohydrolase, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.